Cargando…

The Mesenchymal Niche in Myelodysplastic Syndromes

Myelodysplastic syndromes (MDSs) are clonal disorders characterized by ineffective hematopoiesis, resulting in cytopenias and a risk of developing acute myeloid leukemia. In addition to mutations affecting hematopoietic stem cells (HSCs), numerous studies have highlighted the role of the bone marrow...

Descripción completa

Detalles Bibliográficos
Autores principales:	Friedrich, Chloé, Kosmider, Olivier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320414/ https://www.ncbi.nlm.nih.gov/pubmed/35885544 http://dx.doi.org/10.3390/diagnostics12071639

Ejemplares similares

Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia
por: Chesnais, Virginie, et al.
Publicado: (2012)

Beyond the Niche: Myelodysplastic Syndrome Topobiology in the Laboratory and in the Clinic
por: Flores-Figueroa, Eugenia, et al.
Publicado: (2016)

Bone marrow niches in myelodysplastic syndromes
por: Tosato, Giovanna, et al.
Publicado: (2021)

Molecular dissection of engraftment in a xenograft model of myelodysplastic syndromes
por: Meunier, Mathieu, et al.
Publicado: (2018)

S162: LOSS OF HEMATOPOIETIC PROGENITORS HETEROGENEITY IS AN ADVERSE PROGNOSTIC FACTOR IN MYELODYSPLASTIC SYNDROMES
por: Dussiau, Charles, et al.
Publicado: (2023)

Aging- and Senescence-associated Changes of Mesenchymal Stromal Cells in Myelodysplastic Syndromes
por: Mattiucci, Domenico, et al.
Publicado: (2018)

Mesenchymal Stem Cells in Aplastic Anemia and Myelodysplastic Syndromes: The “Seed and Soil” Crosstalk
por: Fattizzo, Bruno, et al.
Publicado: (2020)

Myelodysplastic Syndromes and Metabolism
por: Balaian, Ekaterina, et al.
Publicado: (2021)

Genetics of Myelodysplastic Syndromes
por: Saygin, Caner, et al.
Publicado: (2021)

Myelodysplastic syndromes and overlap syndromes
por: Chang, Yoon Hwan
Publicado: (2021)

APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis
por: Raimbault, Anna, et al.
Publicado: (2016)

An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome
por: Martini, M, et al.
Publicado: (2015)

VEXAS Syndrome: A Novelty in MDS Landscape
por: Templé, Marie, et al.
Publicado: (2022)

Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS)
por: Valent, Peter, et al.
Publicado: (2010)

Myelodysplastic Syndrome: Diagnosis and Screening
por: Tria, Francisco P., et al.
Publicado: (2022)

Decitabine in the treatment of myelodysplastic syndromes
por: Saba, Hussain I
Publicado: (2007)

Immune Mechanisms in Myelodysplastic Syndrome
por: Glenthøj, Andreas, et al.
Publicado: (2016)

Hereditary Predispositions to Myelodysplastic Syndrome
por: Bannon, Sarah A., et al.
Publicado: (2016)

Prognostic Markers of Myelodysplastic Syndromes
por: Veryaskina, Yuliya Andreevna, et al.
Publicado: (2020)

Genetic basis of myelodysplastic syndromes
por: OGAWA, Seishi
Publicado: (2020)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Reticulocytosis As a Whistleblower: A Rare Case of Acquired Elliptocytosis in a Myelodysplastic Syndrome Patient With Trisomy 8
por: Hage-Sleiman, Mehdi, et al.
Publicado: (2021)

The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome
por: Zheng, Likun, et al.
Publicado: (2022)

Endothelial Progenitor Cell Dysfunction in Myelodysplastic Syndromes: Possible Contribution of a Defective Vascular Niche to Myelodysplasia()()
por: Teofili, Luciana, et al.
Publicado: (2015)

Hypoplastic Myelodysplastic Syndromes: Just an Overlap Syndrome?
por: Fattizzo, Bruno, et al.
Publicado: (2021)

Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
por: Valencia, A, et al.
Publicado: (2014)

Cytogenetic features in myelodysplastic syndromes
por: Haase, Detlef
Publicado: (2008)

New Treatments for Myelodysplastic Syndromes
por: D’Alò, Francesco, et al.
Publicado: (2010)

Molecular Pathogenesis of Myelodysplastic Syndromes
por: Visconte, Valeria, et al.
Publicado: (2014)

Diagnostics and Prognostication of Myelodysplastic Syndromes
por: Zini, Gina
Publicado: (2017)

Emerging Therapies for the Myelodysplastic Syndromes
por: Canaani, Jonathan
Publicado: (2019)

Myelodysplastic syndrome with genetic predisposition
por: Park, Meerim
Publicado: (2021)

Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes
por: Raj, Kavita, et al.
Publicado: (2006)

Safety and efficacy of azacitidine in myelodysplastic syndromes
por: Vigil, Carlos E, et al.
Publicado: (2010)

The Evolving Landscape of Myelodysplastic Syndrome Prognostication
por: Shreve, Jacob, et al.
Publicado: (2020)

Summary of animal models of myelodysplastic syndrome
por: Li, Weisha, et al.
Publicado: (2021)

The Genetics of Myelodysplastic Syndromes: Clinical Relevance
por: Chiereghin, Chiara, et al.
Publicado: (2021)

EnvIRONmental Aspects in Myelodysplastic Syndrome
por: Petzer, Verena, et al.
Publicado: (2021)

Myelodysplastic syndromes
por: Hellström Lindberg, Eva
Publicado: (2018)

Iron Chelation Therapy in Myelodysplastic Syndromes
por: Messa, Emanuela, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_3rgf01vk4qnirjqc4hcdr01ig9